The Role of Circulating Adiponectin and SNP276G>T at
Adiponectin
/ blood
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Biomarkers, Tumor
/ blood
Breast Neoplasms
/ blood
Case-Control Studies
Female
Genetic Predisposition to Disease
Genotype
Humans
Middle Aged
Mutation
Ovarian Neoplasms
/ blood
Polymorphism, Single Nucleotide
Prognosis
Retrospective Studies
ADIPOQ polymorphism
BRCA mutation
BRCA-associated cancer
adipokines
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
03
02
2020
revised:
13
02
2020
accepted:
27
02
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
24
11
2020
Statut:
ppublish
Résumé
Environmental factors may influence the lifetime risk of cancer (penetrance) in women with a BRCA mutation. In 89 BRCA-mutant women, affected or unaffected by breast/ovarian cancer, we explored serum levels of adipokines and their relation with the polymorphism SNP276G>T as modulators of BRCA penetrance. Affected women had significantly lower adiponectin than healthy women. Affected women with rs1501299 TT had significantly lower adiponectin and higher leptin than GT and GG genotypes. GT genotype was significantly associated with the disease status [odds ratio (OR)=3.24, 95% confidence interval (95% CI)=1.03-10.17]. Women in the lower tertile of serum adiponectin had a RR of BRCA-associated cancer of 2.80, 95% CI=1.1-7.1 (p for trend=0.03) compared with women in the higher tertile. In the SNP rs1501299 the T allele was significantly associated with lower serum levels of adiponectin in affected women, suggesting that the T allele might be related to cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Environmental factors may influence the lifetime risk of cancer (penetrance) in women with a BRCA mutation.
MATERIALS AND METHODS
METHODS
In 89 BRCA-mutant women, affected or unaffected by breast/ovarian cancer, we explored serum levels of adipokines and their relation with the polymorphism SNP276G>T as modulators of BRCA penetrance.
RESULTS
RESULTS
Affected women had significantly lower adiponectin than healthy women. Affected women with rs1501299 TT had significantly lower adiponectin and higher leptin than GT and GG genotypes. GT genotype was significantly associated with the disease status [odds ratio (OR)=3.24, 95% confidence interval (95% CI)=1.03-10.17]. Women in the lower tertile of serum adiponectin had a RR of BRCA-associated cancer of 2.80, 95% CI=1.1-7.1 (p for trend=0.03) compared with women in the higher tertile.
CONCLUSION
CONCLUSIONS
In the SNP rs1501299 the T allele was significantly associated with lower serum levels of adiponectin in affected women, suggesting that the T allele might be related to cancer.
Identifiants
pubmed: 32345671
pii: 17/3/301
doi: 10.21873/cgp.20190
pmc: PMC7259884
doi:
Substances chimiques
ADIPOQ protein, human
0
Adiponectin
0
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-307Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Fam Cancer. 2011 Sep;10(3):521-8
pubmed: 21455766
Metabolism. 2008 Jun;57(6):824-30
pubmed: 18502266
Obes Res. 2003 Mar;11(3):368-72
pubmed: 12634431
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):519-530
pubmed: 31659105
DNA Repair (Amst). 2019 Sep;81:102668
pubmed: 31337537
Hum Mol Genet. 2012 Jan 15;21(2):463-71
pubmed: 22010046
Cancer Causes Control. 2015 Mar;26(3):333-44
pubmed: 25579073
Cytokine. 2013 Feb;61(2):565-71
pubmed: 23200411
Metabolism. 2019 Mar;92:121-135
pubmed: 30445141
Nat Rev Immunol. 2006 Oct;6(10):772-83
pubmed: 16998510
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):293-298
pubmed: 28870997
Am J Clin Nutr. 2005 Apr;81(4):780-6
pubmed: 15817852
Breast J. 2017 Jul;23(4):482-483
pubmed: 28121048
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
Oncotarget. 2017 Sep 18;8(60):101255-101261
pubmed: 29254161
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1018-28
pubmed: 27340121
Cancer Genomics Proteomics. 2012 Nov;9(6):383-7
pubmed: 23162077
Breast Cancer Res Treat. 2018 Jun;169(3):561-571
pubmed: 29404807
Fam Cancer. 2015 Mar;14(1):117-28
pubmed: 25373702
Medicine (Baltimore). 2019 Feb;98(5):e14094
pubmed: 30702563
Am J Hum Genet. 2010 Oct 8;87(4):545-52
pubmed: 20887962
Int J Mol Sci. 2017 Jun 21;18(6):
pubmed: 28635626
Atherosclerosis. 2020 Jan;292:1-9
pubmed: 31731079
Clin Chim Acta. 2013 Feb 18;417:80-4
pubmed: 23266767
Diabetes Care. 2005 May;28(5):1022-8
pubmed: 15855561
Obes Res Clin Pract. 2019 Jul - Aug;13(4):329-339
pubmed: 31003933
J Mol Med (Berl). 2005 Sep;83(9):711-9
pubmed: 15877215
JAMA. 2004 Sep 22;292(12):1440-6
pubmed: 15383514
Cancer Res. 2008 May 1;68(9):3178-84
pubmed: 18451143
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22
pubmed: 23628597
Anticancer Res. 2017 Mar;37(3):1281-1287
pubmed: 28314293
Cancer Lett. 2004 Mar 8;205(1):1-8
pubmed: 15040392
Integr Cancer Ther. 2018 Mar;17(1):153-160
pubmed: 28741383
Diabetes. 2002 Jul;51(7):2306-12
pubmed: 12086965
Cancer. 2011 May 1;117(9):1812-8
pubmed: 21509758
Oncotarget. 2017 May 13;8(43):75389-75399
pubmed: 29088874
Br J Nutr. 1974 Jul;32(1):77-97
pubmed: 4843734
J Cancer Epidemiol. 2009;2009:748367
pubmed: 20445803
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Cancers (Basel). 2018 Sep 04;10(9):
pubmed: 30181513
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1195-200
pubmed: 27197293
Rev Bras Ter Intensiva. 2012 Sep;24(3):270-7
pubmed: 23917829